A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer’s Disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2426-0266
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer’s Disease ; volume:9 ; number:3 ; day:17 ; month:5 ; year:2022 ; pages:469-479 ; date:7.2022
The journal of prevention of Alzheimer's disease ; 9, Heft 3 (17.5.2022), 469-479, 7.2022
- Urheber
-
Piccirella, Simona
Van Neste, L.
Fowler, C.
Masters, C. L.
Fripp, J.
Doecke, J. D.
Xiong, C.
Uberti, D.
Kinnon, P.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.14283/jpad.2022.52
- URN
-
urn:nbn:de:101:1-2022092022121117192216
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Piccirella, Simona
- Van Neste, L.
- Fowler, C.
- Masters, C. L.
- Fripp, J.
- Doecke, J. D.
- Xiong, C.
- Uberti, D.
- Kinnon, P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Blood-based molecular biomarkers for Alzheimer’s disease
Blood‐based biomarkers for Alzheimer's disease
Blood-based lipidomic signature of severe obstructive sleep apnoea in Alzheimer’s disease
Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer’s disease
A blood-based composite panel that screens Alzheimer’s disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
The potential impact of clinical factors on blood-based biomarkers for Alzheimer’s disease
The impact of exercise on blood-based biomarkers of Alzheimer’s disease in cognitively unimpaired older adults
An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform
New approaches to symptomatic treatments for Alzheimer’s disease
Patterns of use of symptomatic treatments for Alzheimer's disease dementia (AD)
Exploring small non-coding RNAs as blood-based biomarkers to predict Alzheimer’s disease
Blood-based molecular biomarkers for Alzheimer’s disease
Blood‐based biomarkers for Alzheimer's disease
Blood-based lipidomic signature of severe obstructive sleep apnoea in Alzheimer’s disease
Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer’s disease
A blood-based composite panel that screens Alzheimer’s disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
The potential impact of clinical factors on blood-based biomarkers for Alzheimer’s disease
The impact of exercise on blood-based biomarkers of Alzheimer’s disease in cognitively unimpaired older adults
An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform
New approaches to symptomatic treatments for Alzheimer’s disease
Patterns of use of symptomatic treatments for Alzheimer's disease dementia (AD)
Exploring small non-coding RNAs as blood-based biomarkers to predict Alzheimer’s disease
Blood-based molecular biomarkers for Alzheimer’s disease
Blood‐based biomarkers for Alzheimer's disease
Blood-based lipidomic signature of severe obstructive sleep apnoea in Alzheimer’s disease
Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer’s disease
A blood-based composite panel that screens Alzheimer’s disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
The potential impact of clinical factors on blood-based biomarkers for Alzheimer’s disease
The impact of exercise on blood-based biomarkers of Alzheimer’s disease in cognitively unimpaired older adults
An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform
New approaches to symptomatic treatments for Alzheimer’s disease
Patterns of use of symptomatic treatments for Alzheimer's disease dementia (AD)